FASEB Summer Research Conference on Lysophospholipid Mediators in Health & Diseas

FASEB 健康溶血磷脂介质夏季研究会议

基本信息

  • 批准号:
    7271073
  • 负责人:
  • 金额:
    $ 1.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-01 至 2008-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Conference Objectives: Whereas the emphasis of the 2005 conference was on integrated approaches towards defining the physiological, pathophysiological and therapeutic importance of lysolipid signaling, the 2007 Conference on Bioactive Lysolipids is focused more on recent developments that are beginning to show the therapeutic importance of targeting lysolipid signaling. To bring together students, postdoctoral, junior scientists, and senior investigators with an interest in bioactive lysolipids who work in diverse disciplines. The maturation of genomics and proteomics have provided new tools for understanding metabolism, signal transduction pathways, and functions of lysolipid mediators. Moreover, the study of knockout mice for many of the important receptors and lysolipid metabolic enzymes and recent progress in developing lysolipid-directed therapeutics has provided new approaches to answer a broad range of biological and clinical questions. By bringing researchers together, our conference will increase the speed of scientific discovery in the field by focusing attention on the most pressing issues and highlighting different approaches to studying lysolipid signaling. To promote sharing of unpublished research observations: Lysolipid research is moving extremely fast and there is often a substantial lag between the time discoveries are made at the bench and their description in a peer reviewed research publication that is available to the scientific community. A focused scientific conference such as this is one of the best mechanisms for dissemination of new results. The collegial atmosphere of this conference and the ample opportunities for interaction provide an excellent forum for sharing new and unpublished observations. To identify novel approaches and methods for studying bioactive lysolipids: The unique structural and physicochemical properties of bioactive lysolipids means that specialized techniques are required for their detection, quantitation, imaging and analysis. These include the development of sophisticated mass spectrometry-based analyses and the use of novel fluorescent probes to monitor lysolipid formation and trafficking in cells and tissues. The meeting features presentations from researchers with particular expertise in these areas. To promote new collaborations: Many new reagents and molecular and bioinformatic tools continue to be developed and interactions promoted by this conference will facilitate sharing of these reagents and tools. This will greatly accelerate research progress. Sharing of ideas, tools and reagents between researchers also can catalyze the development of important new collaborations. To identify new therapeutic correlations: The elucidation of the mechanism of action of the immunosuppressant drug FTY720 as a S1P receptor agonist and progress in the development of experimental therapeutics that target LPA and S1P receptors and signaling have put lysolipid signaling at the forefront of drug discovery since a majority of drugs on the market today are targeted toward G proteincoupled receptors. Interactions between basic scientists, pharmacologists, chemists and researchers with interests in clinical and preclinical research promise will surely lead to new therapeutic correlations between lysolipid signaling and disease. To foster the career development of graduate and postgraduate trainees and junior investigators with special emphasis on women, minorities and persons with disabilities: Education and career development is an overarching goal of this conference which provides a unique opportunity for graduate and postgraduate trainees to interact personally with established investigators in the field. Many opportunities are being provided for trainees to present and discuss their research in a supportive but critical atmosphere. Much of the fund raising is aimed at supporting the attendance of younger scientists as well as women, minorities, and disabled persons. As detailed below, the conference has a strong tradition of featuring beginning and junior investigators as speakers and we have a well-developed plan to promote the participation of women and minority investigators in every aspect of this meeting.
描述(由申请人提供):会议目标:虽然2005年会议的重点是定义Lysolipid信号的生理,病理生理和治疗意义的综合方法,但2007年2007年的关于生物活性lysolipids的会议更加集中在最新的发展上,这些发展旨在表现出对具有针对性化质量质量质量质量质量质量质量质量的近期重要性。 召集学生,博士后,初级科学家和高级调查员,对从事多种学科工作的生物活性溶血脂感兴趣。基因组学和蛋白质组学的成熟为理解新陈代谢,信号转导途径和溶血脂介质功能提供了新的工具。此外,对许多重要受体和溶酶体代谢酶的基因敲除小鼠的研究以及开发溶酶体指导的治疗剂的最新进展提供了新的方法来回答广泛的生物学和临床问题。通过将研究人员聚集在一起,我们的会议将通过将注意力集中在最紧迫的问题上,并突出研究溶血脂信号传导的不同方法来提高现场的科学发现速度。 为了促进未发表的研究观​​察的共享:Lysolipid Research的发展非常快,并且在板凳上发现的时间及其在同行评审的研究出版物中进行的描述通常存在很大的滞后,科学界可以使用。这样的专注科学会议是传播新结果的最佳机制之一。这次会议的合作氛围和足够的互动机会为分享新的和未发表的观察结果提供了一个很好的论坛。 为了确定研究生物活性溶酶体的新方法和方法:生物活性溶酶体的独特结构和物理化学特性意味着其检测,定量,成像和分析需要专门的技术。其中包括基于复杂的质谱分析的发展以及使用新型荧光探针来监测细胞和组织中的溶酶体形成和运输。会议的特色是来自这些领域具有特殊专业知识的研究人员的演讲。 为了促进新的合作:许多新试剂以及分子和生物信息学的工具继续开发,本次会议促进的互动将有助于共享这些试剂和工具。这将极大地加速研究进展。研究人员之间的思想,工具和试剂的共享也可以促进重要的新合作的发展。 To identify new therapeutic correlations: The elucidation of the mechanism of action of the immunosuppressant drug FTY720 as a S1P receptor agonist and progress in the development of experimental therapeutics that target LPA and S1P receptors and signaling have put lysolipid signaling at the forefront of drug discovery since a majority of drugs on the market today are targeted toward G proteincoupled receptors.基础科学家,药理学家,化学家和对临床和临床前研究承诺有兴趣的研究人员之间的相互作用肯定会导致溶血脂信号传导和疾病之间的新治疗相关性。 为了促进研究生和研究生学员的职业发展以及特别强调妇女,少数民族和残疾人的初级调查员:教育和职业发展是本次会议的总体目标,为研究生和研究生学员提供了与该领域既定研究者亲自互动的独特机会。为受训者提供了许多机会,可以在支持性但至关重要的氛围中介绍和讨论他们的研究。大部分筹款旨在支持年轻科学家以及妇女,少数民族和残疾人的出席。如下所述,会议具有较强的传统传统,即主张开始和初级调查员,我们制定了一个完善的计划,以促进妇女和少数民族调查员在这次会议的各个方面的参与。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SARAH SPIEGEL其他文献

SARAH SPIEGEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SARAH SPIEGEL', 18)}}的其他基金

Discovery and evaluation of novel therapy for Niemann-Pick type C targeting NPC1
针对 NPC1 的 Niemann-Pick C 型新疗法的发现和评估
  • 批准号:
    8814287
  • 财政年份:
    2014
  • 资助金额:
    $ 1.55万
  • 项目类别:
Roles of sphingosine-1 phosphate phosphohydrolase
1 磷酸鞘氨醇磷酸水解酶的作用
  • 批准号:
    7999977
  • 财政年份:
    2010
  • 资助金额:
    $ 1.55万
  • 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
  • 批准号:
    7691534
  • 财政年份:
    2009
  • 资助金额:
    $ 1.55万
  • 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
  • 批准号:
    8026005
  • 财政年份:
    2009
  • 资助金额:
    $ 1.55万
  • 项目类别:
Training In Functional Lipidomics In Cardiovascular & Respiratory Diseases
心血管功能脂质组学培训
  • 批准号:
    8426144
  • 财政年份:
    2009
  • 资助金额:
    $ 1.55万
  • 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
  • 批准号:
    8259149
  • 财政年份:
    2009
  • 资助金额:
    $ 1.55万
  • 项目类别:
Training in functional lipidomics in cardiovascular and respiratory diseases
心血管和呼吸系统疾病功能脂质组学培训
  • 批准号:
    7817135
  • 财政年份:
    2009
  • 资助金额:
    $ 1.55万
  • 项目类别:
Targeting Sphingosine and Ceramide Kinases and Inflammation
靶向鞘氨醇和神经酰胺激酶和炎症
  • 批准号:
    7476204
  • 财政年份:
    2008
  • 资助金额:
    $ 1.55万
  • 项目类别:
4000 Q TRAP LC/MS/MS SHARED MASS SPECTROMETER: DRUG ABUSE, CANNABINOIDS
4000 Q TRAP LC/MS/MS 共享质谱仪:药物滥用、大麻素
  • 批准号:
    7335028
  • 财政年份:
    2006
  • 资助金额:
    $ 1.55万
  • 项目类别:
4000 Q TRAP LC/MS/MS shared mass spectrometer
4000 Q TRAP LC/MS/MS 共用质谱仪
  • 批准号:
    7034061
  • 财政年份:
    2006
  • 资助金额:
    $ 1.55万
  • 项目类别:

相似国自然基金

跨区域调水工程与区域经济增长:效应测度、机制探究与政策建议
  • 批准号:
    72373114
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
农产品区域公用品牌地方政府干预机制与政策优化研究
  • 批准号:
    72373068
  • 批准年份:
    2023
  • 资助金额:
    41 万元
  • 项目类别:
    面上项目
新型城镇化与区域协调发展的机制与治理体系研究
  • 批准号:
    72334006
  • 批准年份:
    2023
  • 资助金额:
    167 万元
  • 项目类别:
    重点项目
我国西南地区节点城市在次区域跨国城市网络中的地位、功能和能级提升研究
  • 批准号:
    72364037
  • 批准年份:
    2023
  • 资助金额:
    28 万元
  • 项目类别:
    地区科学基金项目
多时序CT联合多区域数字病理早期预测胃癌新辅助化疗抵抗的研究
  • 批准号:
    82360345
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
  • 批准号:
    10637938
  • 财政年份:
    2023
  • 资助金额:
    $ 1.55万
  • 项目类别:
A highly opioid responsive VTA projection to the dorsal endopiriform nucleus.
高度阿片类药物反应的 VTA 投射到背内核状核。
  • 批准号:
    10739039
  • 财政年份:
    2023
  • 资助金额:
    $ 1.55万
  • 项目类别:
Gabapentinoid/opioid mixtures: abuse and toxicity
加巴喷丁/阿片类混合物:滥用和毒性
  • 批准号:
    10639396
  • 财政年份:
    2023
  • 资助金额:
    $ 1.55万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10696455
  • 财政年份:
    2023
  • 资助金额:
    $ 1.55万
  • 项目类别:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
  • 批准号:
    10843438
  • 财政年份:
    2023
  • 资助金额:
    $ 1.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了